VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $934,055 | +3.8% | 18,322 | +1.7% | 0.00% | 0.0% |
| Q2 2023 | $899,919 | +71.6% | 18,020 | +28.8% | 0.00% | +50.0% |
| Q1 2023 | $524,345 | -30.6% | 13,990 | -11.2% | 0.00% | -33.3% |
| Q4 2022 | $755,692 | +188.4% | 15,760 | +44.2% | 0.00% | +200.0% |
| Q3 2022 | $262,000 | +14.9% | 10,927 | +4.4% | 0.00% | 0.0% |
| Q2 2022 | $228,000 | -31.7% | 10,463 | -24.3% | 0.00% | 0.0% |
| Q1 2022 | $334,000 | -13.7% | 13,827 | -14.9% | 0.00% | 0.0% |
| Q4 2021 | $387,000 | -6.5% | 16,255 | -0.4% | 0.00% | 0.0% |
| Q3 2021 | $414,000 | -5.9% | 16,327 | -16.5% | 0.00% | 0.0% |
| Q2 2021 | $440,000 | +50.7% | 19,544 | +32.1% | 0.00% | 0.0% |
| Q1 2021 | $292,000 | -7.6% | 14,794 | +24.4% | 0.00% | 0.0% |
| Q4 2020 | $316,000 | – | 11,897 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |